Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
|---|---|---|---|---|---|
| PGF-H52G3 | Human | Human PlGF-1 Protein, GST Tag |  |
||
| PGF-H5255 | Human | Human PLGF-3 Protein, Fc Tag (MALS verified) |  |
|
|
| PGF-H5256 | Human | Human PlGF-1 Protein, Fc Tag (MALS verified) |  |
|
|
| PGF-H52H5 | Human | Human PlGF-1 Protein, His Tag (MALS verified) |  |
|
|
| PGF-M52H0 | Mouse | Mouse PLGF / PGF Protein, His Tag |  |
|
|
| PGF-R52H0 | Rhesus macaque | Rhesus macaque PLGF / PGF Protein, His Tag |  |
|
|
| PGF-H5229 | Human | Human PlGF-2 Protein, His Tag |  |
|
Immobilized Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) at 2 μg/mL (100 μL/well) can bind Human PlGF-1 Protein, Fc Tag (Cat. No. PGF-H5256) with a linear range of 0.1-3 ng/mL (QC tested).
The purity of Human PLGF-3 Protein, Fc Tag (Cat. No. PGF-H5255) is more than 85% and the molecular weight of this protein is around 115-130 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Approved | Momenta, Mylan Nv | EU | Diabetes Complications; Myopia, Degenerative; Diabetic Retinopathy; Macular Edema; Retinal Vein Occlusion | Viatris Ltd | 2023-09-15 | Macular Edema; Myopia, Degenerative; Diabetic macular oedema; Diabetes Complications; Diabetic Retinopathy; Retinal Vein Occlusion | Details | |
| Aflibercept biosimilar (Qilu Pharmaceutical) | QL-1207 | Approved | Qilu Pharmaceutical Co Ltd | Mainland China | Macular Degeneration; Diabetic macular oedema | Qilu Pharmaceutical Co Ltd | 2023-12-13 | Diabetic macular oedema; Macular Degeneration | Details | |
| Aflibercept | BAY-865321; BAT-86-5321 | Approved | Bayer AG | Eylea, 艾力雅 | United States | Macular Degeneration; Macular Edema | Regeneron Pharmaceuticals Inc | 2011-11-18 | Retinitis Pigmentosa; Choroidal Neovascularization; Carcinoma, Non-Small-Cell Lung; Corneal Neovascularization; Retinopathy of Prematurity; Neoplasm Metastasis; Diabetic Retinopathy; Retinal Vein Occlusion; Macular Degeneration; Vitreous Hemorrhage; Lymphoma, Non-Hodgkin; Retinal Degeneration; Eye Diseases; Diabetes Complications; Colorectal Neoplasms; Prostatic Neoplasms; Diabetes Mellitus, Type 1; Wet Macular Degeneration; Diabetic macular oedema; Multiple Myeloma; Myopia, Degenerative; Retinal Diseases; Colonic Neoplasms; Central Serous Chorioretinopathy; Neoplasms; Diabetes Mellitus, Type 2; Rectal Neoplasms; Choroid Diseases; Glaucoma, Neovascular; Macular Edema; Cataract | Details |
| Ziv-aflibercept | BAY-865321; AVE-0005 | Approved | Sanofi | Zaltrap | United States | Colorectal Neoplasms | Sanofi-Aventis U.S. Llc | 2012-08-03 | Lymphoma; Breast Neoplasms; Urethral Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Carcinoma, Mucoepidermoid; Gliosarcoma; Astrocytoma; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Peritoneal Neoplasms; Ureteral Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Glioma; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Carcinoma, Squamous Cell; Retinal Vein Occlusion; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Solid tumours; Leiomyosarcoma; Multiple Endocrine Neoplasia Type 1; Leukemia; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Rectal Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Leukemia, Myelomonocytic, Chronic; Ovarian Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Carcinoma, Transitional Cell; Carcinoma, Papillary; Small Cell Lung Carcinoma; Colonic Neoplasms; Ascites; Lung Diseases; Adenoc | Details |
| Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Approved | Momenta, Mylan Nv | EU | Diabetes Complications; Myopia, Degenerative; Diabetic Retinopathy; Macular Edema; Retinal Vein Occlusion | Viatris Ltd | 2023-09-15 | Macular Edema; Myopia, Degenerative; Diabetic macular oedema; Diabetes Complications; Diabetic Retinopathy; Retinal Vein Occlusion | Details | |
| Aflibercept biosimilar (Qilu Pharmaceutical) | QL-1207 | Approved | Qilu Pharmaceutical Co Ltd | Mainland China | Macular Degeneration; Diabetic macular oedema | Qilu Pharmaceutical Co Ltd | 2023-12-13 | Diabetic macular oedema; Macular Degeneration | Details | |
| Aflibercept | BAY-865321; BAT-86-5321 | Approved | Bayer AG | Eylea, 艾力雅 | United States | Macular Degeneration; Macular Edema | Regeneron Pharmaceuticals Inc | 2011-11-18 | Retinitis Pigmentosa; Choroidal Neovascularization; Carcinoma, Non-Small-Cell Lung; Corneal Neovascularization; Retinopathy of Prematurity; Neoplasm Metastasis; Diabetic Retinopathy; Retinal Vein Occlusion; Macular Degeneration; Vitreous Hemorrhage; Lymphoma, Non-Hodgkin; Retinal Degeneration; Eye Diseases; Diabetes Complications; Colorectal Neoplasms; Prostatic Neoplasms; Diabetes Mellitus, Type 1; Wet Macular Degeneration; Diabetic macular oedema; Multiple Myeloma; Myopia, Degenerative; Retinal Diseases; Colonic Neoplasms; Central Serous Chorioretinopathy; Neoplasms; Diabetes Mellitus, Type 2; Rectal Neoplasms; Choroid Diseases; Glaucoma, Neovascular; Macular Edema; Cataract | Details |
| Ziv-aflibercept | BAY-865321; AVE-0005 | Approved | Sanofi | Zaltrap | United States | Colorectal Neoplasms | Sanofi-Aventis U.S. Llc | 2012-08-03 | Lymphoma; Breast Neoplasms; Urethral Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Carcinoma, Mucoepidermoid; Gliosarcoma; Astrocytoma; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Peritoneal Neoplasms; Ureteral Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Glioma; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Carcinoma, Squamous Cell; Retinal Vein Occlusion; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Solid tumours; Leiomyosarcoma; Multiple Endocrine Neoplasia Type 1; Leukemia; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Rectal Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Leukemia, Myelomonocytic, Chronic; Ovarian Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Carcinoma, Transitional Cell; Carcinoma, Papillary; Small Cell Lung Carcinoma; Colonic Neoplasms; Ascites; Lung Diseases; Adenoc | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Aflibercept biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
| Aflibercept biosimilar (Amgen) | ABP-938 | Phase 3 Clinical | Amgen Inc | Vascular Diseases; Macular Degeneration | Details |
| Aflibercept Biosimilar(Alvotech Swiss) | AVT-06 | Phase 3 Clinical | Alvotech Swiss Ag | Vascular Diseases; Macular Degeneration | Details |
| Aflibercept biosimilar (HEXAL/Sandoz) | SOK-583A1; SOK583A1; SOK-583 | Phase 3 Clinical | Sandoz, Hexal | Macular Degeneration | Details |
| CT-P42 | CT-P42 | Phase 3 Clinical | Celltrion Inc | Macular Edema; Diabetic macular oedema | Details |
| Aflibercept biosimilar (Mabwell) | 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Diabetic macular oedema | Details |
| FYB-203 | FYB-203 | Phase 3 Clinical | Macular Degeneration | Details | |
| Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Phase 3 Clinical | Sam Chun Dang Pharm Co Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
| Aflibercept biosimilar (Samsung Bioepis) | SB-15; AM003; SB15 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Solid tumours; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details |
| Aflibercept Biosimilar (Boan Biopharma/Luye Pharma） | LY-09004; BA-9101; OT-702 | Phase 3 Clinical | Luye Pharma Group Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
| Anti-placental growth factor monoclonal antibody | αPlGF; R-7334; TB-403; RG-7334; THR-317; RO-5323441 | Phase 2 Clinical | Thrombogenics, Bioinvent International Ab | Retinal Telangiectasis; Ovarian Neoplasms; Solid tumours; Medulloblastoma; Macular Edema; Glioblastoma; Colorectal Neoplasms; Diabetic Retinopathy; Diabetes Mellitus; Macular Degeneration; Carcinoma, Hepatocellular | Details |
| 4D-150 | 4D-150 | Phase 2 Clinical | 4d Molecular Therapeutics Inc | Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy | Details |
| Ziv-aflibercept biosimiliar (Boan Biopharma) | LY-01012; BA-1103 | Phase 1 Clinical | Colorectal Neoplasms | Details | |
| PB-101 | PB-101 | Phase 1 Clinical | Panolos Bioscience Inc | Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
| Aflibercept biosimilar (Zein Bioteccnology) | Phase 1 Clinical | Zein Bioteccnology Co Ltd | Diabetic macular oedema | Details | |
| Aflibercept biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
| Aflibercept biosimilar (Amgen) | ABP-938 | Phase 3 Clinical | Amgen Inc | Vascular Diseases; Macular Degeneration | Details |
| Aflibercept Biosimilar(Alvotech Swiss) | AVT-06 | Phase 3 Clinical | Alvotech Swiss Ag | Vascular Diseases; Macular Degeneration | Details |
| Aflibercept biosimilar (HEXAL/Sandoz) | SOK-583A1; SOK583A1; SOK-583 | Phase 3 Clinical | Sandoz, Hexal | Macular Degeneration | Details |
| CT-P42 | CT-P42 | Phase 3 Clinical | Celltrion Inc | Macular Edema; Diabetic macular oedema | Details |
| Aflibercept biosimilar (Mabwell) | 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Diabetic macular oedema | Details |
| FYB-203 | FYB-203 | Phase 3 Clinical | Macular Degeneration | Details | |
| Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Phase 3 Clinical | Sam Chun Dang Pharm Co Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
| Aflibercept biosimilar (Samsung Bioepis) | SB-15; AM003; SB15 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Solid tumours; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details |
| Aflibercept Biosimilar (Boan Biopharma/Luye Pharma） | LY-09004; BA-9101; OT-702 | Phase 3 Clinical | Luye Pharma Group Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
| Anti-placental growth factor monoclonal antibody | αPlGF; R-7334; TB-403; RG-7334; THR-317; RO-5323441 | Phase 2 Clinical | Thrombogenics, Bioinvent International Ab | Retinal Telangiectasis; Ovarian Neoplasms; Solid tumours; Medulloblastoma; Macular Edema; Glioblastoma; Colorectal Neoplasms; Diabetic Retinopathy; Diabetes Mellitus; Macular Degeneration; Carcinoma, Hepatocellular | Details |
| 4D-150 | 4D-150 | Phase 2 Clinical | 4d Molecular Therapeutics Inc | Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy | Details |
| Ziv-aflibercept biosimiliar (Boan Biopharma) | LY-01012; BA-1103 | Phase 1 Clinical | Colorectal Neoplasms | Details | |
| PB-101 | PB-101 | Phase 1 Clinical | Panolos Bioscience Inc | Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
| Aflibercept biosimilar (Zein Bioteccnology) | Phase 1 Clinical | Zein Bioteccnology Co Ltd | Diabetic macular oedema | Details |
This web search service is supported by Google Inc.
A-Z
